Recent Updates — LUCD

Lucid Diagnostics raised approximately $15 million by selling 15,000 shares of newly designated Series C Convertible Preferred Stock to accredited investors on October 21, 2026. The shares carry a stated value of $1,000 and convert into common stock at an initial price of $0.3519 per share. The issuance triggers a reduction in the conversion price of existing senior secured convertible notes due 2029 to match this new floor. Holders are entitled to cumulative dividends payable in shares or cash, with a mandatory conversion feature if the common stock VWAP reaches $5.00 for 20 out of 30 consecutive trading days after 24 months. The company operates in the diagnostic testing industry.

On October 12, 2026, Nasdaq notified Lucid Diagnostics that its common stock closed below $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2). The company has until April 12, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive trading days. Failure to meet this requirement may result in delisting proceedings. Lucid Diagnostics operates in the diagnostics industry.

Lucid Diagnostics Inc. held its annual meeting of stockholders on June 24, 2026, with approximately 84.7% of outstanding shares represented. Stockholders approved an amendment to the certificate of incorporation to increase authorized common stock from 300,000,000 to 400,000,000 shares. Additionally, the meeting resulted in the re-election of Class B directors James L. Cox, M.D., John R. Palumbo, and Ronald M. Sparks, and the ratification of CBIZ CPAs P.C. as the independent accounting firm for the fiscal year ending December 31, 2025. Lucid Diagnostics Inc. is a medical technology company focused on diagnostic solutions.